Stock listing
Scinopharm Taiwan, Ltd.
Selected listing: 1789 · TWSE · TWD · TW
Scinopharm Taiwan, Ltd. (TWSE:1789), Health Technology. Latest release Jan 5, 2026: ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection…
- Ticker
- TWSE:1789
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- TWSE
- Currency
- TWD
About Scinopharm Taiwan, Ltd.
Scinopharm Taiwan, Ltd. is a publicly traded company on the Taiwan stock market under the ticker 1789. Scinopharm specializes in the development and manufacturing of pharmaceutical products, contributing to the healthcare sector in Taiwan and beyond.
Latest news from Scinopharm Taiwan, Ltd.
ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis
January 5, 2026
ScinoPharm Taiwan : Board of Directors approved the company's consolidated financial report of Q2, 2022
August 5, 2022
ScinoPharm Taiwan : To Announce the ex-dividend record date and cash dividend distribution date approved by the Board of Directors
May 30, 2022
ScinoPharm Taiwan : Announce the Company's 2022 Shareholders' Meeting approved to release the Directors and their representatives from non-competition restrictions
May 30, 2022
Scinopharm Taiwan : President & CEO Dr. Jo Shen to Retire, Dr. Yung-Fa (Fred) Chen to Succeed
July 11, 2014
Research Scinopharm Taiwan, Ltd.
Scinopharm Taiwan, Ltd. company profile
View the public company page for Scinopharm Taiwan, Ltd. on 6ix.
Scinopharm Taiwan, Ltd. news
Read company news and market updates connected to Scinopharm Taiwan, Ltd..
Scinopharm Taiwan, Ltd. investor events
Find investor webinars, events, and replay context for Scinopharm Taiwan, Ltd..